Nan Fung Group Holdings Ltd Acquires 20,000 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Nan Fung Group Holdings Ltd lifted its stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 183.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 30,875 shares of the company's stock after buying an additional 20,000 shares during the quarter. Kymera Therapeutics comprises 1.0% of Nan Fung Group Holdings Ltd's portfolio, making the stock its 25th largest position. Nan Fung Group Holdings Ltd's holdings in Kymera Therapeutics were worth $1,242,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently bought and sold shares of the company. Blue Trust Inc. boosted its position in Kymera Therapeutics by 74.8% during the 4th quarter. Blue Trust Inc. now owns 631 shares of the company's stock valued at $25,000 after acquiring an additional 270 shares in the last quarter. KBC Group NV boosted its position in shares of Kymera Therapeutics by 53.8% during the fourth quarter. KBC Group NV now owns 2,151 shares of the company's stock valued at $87,000 after purchasing an additional 752 shares in the last quarter. Summit Investment Advisors Inc. boosted its position in shares of Kymera Therapeutics by 9.0% during the fourth quarter. Summit Investment Advisors Inc. now owns 4,912 shares of the company's stock valued at $198,000 after purchasing an additional 406 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S purchased a new stake in Kymera Therapeutics in the fourth quarter worth $251,000. Finally, PEAK6 LLC bought a new position in Kymera Therapeutics in the fourth quarter worth $302,000.

Insiders Place Their Bets

In other Kymera Therapeutics news, CFO Bruce N. Jacobs sold 7,035 shares of the company's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total value of $214,215.75. Following the completion of the transaction, the chief financial officer now directly owns 201,886 shares in the company, valued at $6,147,428.70. This represents a 3.37 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Jeremy G. Chadwick sold 1,383 shares of the firm's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total transaction of $42,112.35. Following the sale, the chief operating officer now owns 67,800 shares in the company, valued at $2,064,510. The trade was a 2.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 10,659 shares of company stock worth $324,567. Company insiders own 15.82% of the company's stock.

Kymera Therapeutics Stock Performance

Shares of NASDAQ KYMR traded up $1.90 during midday trading on Wednesday, hitting $30.70. 1,017,101 shares of the stock traded hands, compared to its average volume of 552,764. The firm has a market capitalization of $1.99 billion, a P/E ratio of -13.12 and a beta of 2.22. Kymera Therapeutics, Inc. has a one year low of $19.45 and a one year high of $53.27. The firm has a 50-day moving average of $30.15 and a two-hundred day moving average of $38.79.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last announced its earnings results on Thursday, February 27th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.12). Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The firm had revenue of $7.39 million during the quarter, compared to analysts' expectations of $14.81 million. Equities analysts forecast that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the stock. HC Wainwright boosted their target price on shares of Kymera Therapeutics from $54.00 to $60.00 and gave the company a "buy" rating in a report on Friday, February 28th. Leerink Partners restated an "outperform" rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a report on Friday, December 27th. Citigroup started coverage on shares of Kymera Therapeutics in a report on Thursday, March 13th. They set a "buy" rating and a $52.00 target price for the company. Finally, Stephens restated an "overweight" rating and issued a $60.00 price target on shares of Kymera Therapeutics in a research note on Tuesday, January 21st. Three research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $56.36.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.